DNB Asset Management AS Buys 9,326 Shares of Gilead Sciences, Inc. $GILD

DNB Asset Management AS raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 254,443 shares of the biopharmaceutical company’s stock after buying an additional 9,326 shares during the period. DNB Asset Management AS’s holdings in Gilead Sciences were worth $31,230,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in GILD. Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at $28,000. Financial Consulate Inc. grew its holdings in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. grew its holdings in shares of Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares during the last quarter. BOCHK Asset Management Ltd bought a new position in shares of Gilead Sciences during the 4th quarter valued at $31,000. Finally, MTM Investment Management LLC grew its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares of the company’s stock, valued at $24,835,883.36. This represents a 1.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the insider directly owned 128,779 shares of the company’s stock, valued at $18,152,687.84. The trade was a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,000 shares of company stock valued at $9,238,250 in the last quarter. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 1.9%

Shares of GILD opened at $129.58 on Friday. The stock has a market capitalization of $160.88 billion, a P/E ratio of 17.65 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a fifty day simple moving average of $137.76 and a two-hundred day simple moving average of $133.22. Gilead Sciences, Inc. has a twelve month low of $100.23 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post -0.78 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Weiss Ratings raised shares of Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, May 11th. UBS Group increased their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a report on Monday, January 26th. Truist Financial reaffirmed a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Leerink Partners reduced their target price on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $157.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.